nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

05.01.2022 | COVID-19 | Original Article Zur Zeit gratis

Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson’s disease (PD) do not overlap

verfasst von: Silvia Morbelli, Silvia Chiola, Maria Isabella Donegani, Dario Arnaldi, Matteo Pardini, Raffaele Mancini, Francesco Lanfranchi, Francesca D’amico, Matteo Bauckneht, Alberto Miceli, Erica Biassoni, Beatrice Orso, Emanuela Barisione, Luana Benedetti, Sambuceti Gianmario, Flavio Nobili

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hyposmia is a common feature of COVID-19 and Parkinson’s disease (PD). As parkinsonism has been reported after COVID-19, a link has been hypothesized between SARS-CoV2 infection and PD. We aimed to evaluate brain metabolic correlates of isolated persistent hyposmia after mild-to-moderate COVID-19 and to compare them with metabolic signature of hyposmia in drug-naïve PD patients.

Methods

Forty-four patients who experienced hyposmia after SARS-COV2 infection underwent brain [¹⁸F]-FDG PET in the first 6 months after recovery. Olfaction was assessed by means of the 16-item “Sniffin’ Sticks” test and patients were classified as with or without persistent hyposmia (COVID-hyposmia and COVID-no-hyposmia respectively). Brain [¹⁸F]-FDG PET of post-COVID subgroups were compared in SPM12. COVID-hyposmia patients were also compared with eighty-two drug-naïve PD patients with hyposmia. Multiple regression analysis was used to identify correlations between olfactory test scores and brain metabolism in patients’ subgroups.

Results

COVID-hyposmia patients (n = 21) exhibited significant hypometabolism in the bilateral gyrus rectus and orbitofrontal cortex with respect to COVID-non-hyposmia (n = 23) (p < 0.002) and in middle and superior temporal gyri, medial/middle frontal gyri, and right insula with respect to PD-hyposmia (p < 0.012). With respect to COVID-hyposmia, PD-hyposmia patients showed hypometabolism in inferior/middle occipital gyri and cuneus bilaterally. Olfactory test scores were directly correlated with metabolism in bilateral rectus and medial frontal gyri and in the right middle temporal and anterior cingulate gyri in COVID-hyposmia patients (p < 0.006) and with bilateral cuneus/precuneus and left lateral occipital cortex in PD-hyposmia patients (p < 0.004).

Conclusion

Metabolic signature of persistent hyposmia after COVID-19 encompasses cortical regions involved in olfactory perception and does not overlap metabolic correlates of hyposmia in PD.

Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–83.CrossRefPubMedPubMedCentral

Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277:2251–61.CrossRefPubMedPubMedCentral

Boscolo-Rizzo P, Polesel J, Spinato G, Menegaldo A, Fabbris C, Calvanese L, Borsetto D, Hopkins C. Predominance of an altered sense of smell or taste among long-lasting symptoms in patients with mildly symptomatic COVID-19. Rhinology. 2020;58:524–5.CrossRefPubMed

Estiri H, Strasser ZH, Brat GA, Semenov YR, Patel CJ, Murphy SN. Evolving phenotypes of non-hospitalized patients that indicate long COVID 2021. https://doi.org/10.1101/2021.04.25.21255923

Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020;9:100163.CrossRefPubMedPubMedCentral

Guedj E, Lazarini F, Morbelli S, Ceccaldi M, Hautefort C, Kas A, Radulesco T, Salmon-Ceron D, Eldin C. Long COVID and the brain network of Proust’s madeleine: targeting the olfactory pathway. Clin Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.05.015.CrossRefPubMedPubMedCentral

Morbelli S, Ekmekcioglu O, Barthel H, Albert NL, Boellaard R, Cecchin D, Guedj E, Lammertsma AA, Law I, Penuelas I, Semah F, Traub-Weidinger T, van de Giessen E, Varrone A, Garibotto V, EANM Neuroimaging Committee. COVID-19 and the brain: impact on nuclear medicine in neurology. Eur J Nucl Med Mol Imaging. 2020;47:2487–92.CrossRefPubMedPubMedCentral

Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, Raoult D. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imaging. 2021;48:592–5.CrossRefPubMed

Niesen M, Trotta N, Noel A, Coolen T, Fayad G, Leurkin-Sterk G, Delpierre I, Henrard S, Sadeghi N, Goffard JC, Goldman S, De Tiège X. Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell. Eur J Nucl Med Mol Imaging. 2021;48:1890–901.CrossRefPubMedPubMedCentral

10.

Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, Guis S, Barthelemy F, Habert P, Ceccaldi M, Million M, Raoult D, Cammilleri S, Eldin C. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48:2823–33.CrossRefPubMedPubMedCentral

11.

Yousefi-Koma A, Haseli S, Bakhshayeshkaram M, Raad N, Karimi-Galougahi M. Multimodality imaging with PET/CT and MRI reveals hypometabolism in tertiary olfactory cortex in parosmia of COVID-19. Acad Radiol. 2021;28:749–51.CrossRefPubMedPubMedCentral

12.

Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Chiola S, Gelardi F, Chiti A. Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. Eur J Nucl Med Mol Imaging. 2021;7:1–11.

13.

Blazhenets G, Schroeter N, Bormann T, Thurow J, Wagner D, Frings L, Weiller C, Meyer PT, Dressing A, Hosp JA. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med. 2021;62:910–5.CrossRefPubMedPubMedCentral

14.

Donegani MI, Miceli A, Pardini M, Bauckneht M, Chiola S, Pennone M, Marini C, Massa F, Raffa S, Ferrarazzo G, Arnaldi D, Sambuceti G, Nobili F, Morbelli S. Brain metabolic correlates of persistent olfactory dysfunction after SARS-Cov2 infection. Biomedicines. 2021;9:287.CrossRefPubMedPubMedCentral

15.

Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, Thurow J, Wagner D, Waller C, Niesen WD, Frings L, Urbach H, Prinz M, Weiller C, Schroeter N, Meyer PT. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 202;144:1263–1276.

16.

Varghese J, Sandmann S, Ochs K, Schrempf IM, Frömmel C, Dugas M, Schmidt HH, Vollenberg R, Tepasse PR. Persistent symptoms and lab abnormalities in patients who recovered from COVID-19. Sci Rep. 2021;11:12775.CrossRefPubMedPubMedCentral

17.

Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol. 1998;55:84–90.CrossRefPubMed

18.

Utsumi K, Fukatsu R, Yamada R, Takamaru Y, Hara Y, Yasumura S. Characteristics of initial symptoms and symptoms at diagnosis in probable dementia with Lewy body disease: incidence of symptoms and gender differences. Psychogeriatrics. 2020;20(5):737–45.CrossRefPubMed

19.

Walker IM, Fullard ME, Morley JF, Duda JE. Olfaction as an early marker of Parkinson’s disease and Alzheimer’s disease. Handb Clin Neurol. 2021;182:317–29.CrossRefPubMed

20.

Nobili F, Morbelli S, Arnaldi D, Ferrara M, Campus C, Brugnolo A, Mazzei D, Mehrdad N, Sambuceti G, Rodriguez G. Radionuclide brain imaging correlates of cognitive impairment in Parkinson’s disease (PD). J Neurol Sci. 2011;310:31–5.CrossRefPubMed

21.

Meles SK, Renken RJ, Pagani M, Teune LK, Arnaldi D, Morbelli S, Nobili F, van Laar T, Obeso JA, Rodríguez-Oroz MC, Leenders KL. Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts. Eur J Nucl Med Mol Imaging. 2020;47:437–50.CrossRefPubMed

22.

Rebholz H, Braun RJ, Ladage D, Knoll W, Kleber C, Hassel AW. Loss of olfactory function-early indicator for COVID-19, other viral infections and neurodegenerative disorders. Front Neurol. 2020;11:569333.CrossRefPubMedPubMedCentral

23.

Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson’s disease: facts and fantasy. Lancet Neurol. 2021;20:94–5.CrossRefPubMed

24.

Morassi M, Palmerini F, Nici S, Magni E, Savelli G, Guerra UP, Chieregato M, Morbelli S, Vogrig A. SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol. 2021;21:1–8.

25.

Makhoul K, Jankovic J. Parkinson’s disease after COVID-19. J Neurol Sci. 2021;422:117331.CrossRefPubMed

26.

Cohen ME, Eichel R, Steiner-Birmanns B, et al. A case of probable Parkinson’s disease after SARS-CoV-2 infection. Lancet Neurol. 2020;19:804–5.CrossRefPubMedPubMedCentral

27.

Faber I, Brandão PRP, Menegatti F, et al. Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Mov Disord. 2020;35:1721–2.CrossRefPubMed

28.

Gandhi RT, Lynch JB, del Rio C. Mild or moderate COVID-19. NEJM. 2020;383(18):1757e66.CrossRef

29.

Orso B, Arnaldi D, Girtler N, Brugnolo A, Doglione E, Mattioli P, Biassoni E, Fancellu R, Massa F, Bauckneht M, Chiola S, Morbelli S, Nobili F, Pardini M. Dopaminergic and serotonergic degeneration and cortical [18F]fluorodeoxyglucose positron emission tomography in de novo Parkinson’s disease. Mov Disord. 2021. https://doi.org/10.1002/mds.28654 (Epub ahead of print).CrossRefPubMed

30.

Kobal G, Hummel T, Sekinger B, et al. “Sniff Sticks”: screening of olfactory performance. Rhinology. 1996;34:222–6.PubMed

31.

Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. Updated Sniffin’ Sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol. 2019;276:719–28.CrossRefPubMed

32.

Briner HR, Simmen D. Smell diskettes as screening test of olfaction. Rhinology. 1999;37:145–8.PubMed

33.

Arnaldi D, Morbelli S, Brugnolo A, Girtler N, Picco A, Ferrara M, Accardo J, Buschiazzo A, de Carli F, Pagani M, Nobili F. Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson’s disease and probable RBD. Parkinsonism Relat Disord. 2016;29:47–53.CrossRefPubMed

34.

Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10.CrossRefPubMed

35.

Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RS. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1994;2:189–210.CrossRef

36.

Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, Caroli A, Frisoni G, Rodriguez G, Nobili F. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging. 2010;37:36–45.CrossRefPubMed

37.

Toniolo S, Scarioni M, Di Lorenzo F, Hort J, Georges J, Tomic S, Nobili F, Frederiksen KS, Management Group of the EAN Dementia and Cognitive Disorders Scientific Panel. Dementia and COVID-19, a bidirectional liaison: risk factors, biomarkers, and optimal health care. J Alzheimers Dis. 2021. https://doi.org/10.3233/JAD-210335 (Epub ahead of print).CrossRefPubMed

38.

Tiraboschi P, Corso A, Guerra UP, Nobili F, Piccardo A, Calcagni ML, Volterrani D, Cecchin D, Tettamanti M, Antelmi L, Vidale S, Sacco L, Merello M, Stefanini S, Micheli A, Vai P, Capitanio S, Gabanelli SV, Riva R, Pinto P, Biffi AM, Muscio C, SCILLA Working Group. (123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with Lewy bodies from other dementias: A comparative study. Ann Neurol. 2016;80:368–78.CrossRefPubMed

39.

Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, Brooks DJ, Darcourt J, Dickson JC, Douglas D, Drzezga A, Dubroff J, Ekmekcioglu O, Garibotto V, Herscovitch P, Kuo P, Lammertsma A, Pappata S, Peñuelas I, Seibyl J, Semah F, Tossici-Bolt L, Van de Giessen E, Van Laere K, Varrone A, Wanner M, Zubal G, Law I. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912.CrossRefPubMedPubMedCentral

40.

Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Park Dis. 2020;10:351–4.

41.

Hainque E, Grabli D. Rapid worsening in Parkinson’s disease may hide COVID-19 infection. Parkinsonism Relat Disord. 2020;S1353–8020:30117–26.

42.

Paschen L, Schmidt N, Wolff S, Cnyrim C, van Eimeren T, Zeuner KE, et al. The olfactory bulb volume in patients with idiopathic Parkinson’s disease. Eur J Neurol. 2015;22:1068–73.CrossRefPubMed

43.

Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. JAMA Neurol. 2020;77:1028–9.CrossRefPubMed

44.

Crespo Cuevas AM, Ispierto L, Vilas D, Planas A, Planas A, Isern I, Sanchez J, De Haro J, Alvarez R. Distinctive olfactory pattern in Parkinson’s disease and non-neurodegenerative causes of hyposmia. Neurodegener Dis. 2018;18:143–9.CrossRefPubMed

45.

Haghshomar M, Dolatshahi M, Ghazi Sherbaf F, Sanjari Moghaddam H, Shirin Shandiz M, Aarabi MH. Disruption of inferior longitudinal fasciculus microstructure in Parkinson’s disease: a systematic review of diffusion tensor imaging studies. Front Neurol. 2018;9:598.CrossRefPubMedPubMedCentral

46.

Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, Frey KA. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133:1747–54.CrossRefPubMedPubMedCentral

47.

Postuma R, Gagnon JF. Cognition and olfaction in Parkinson’s disease. Brain. 2010;133:e160.CrossRefPubMed

48.

Richard L. Doty, Olfaction in Richard L. Doty, Olfaction, Editor(s). Encyclopedia of the human brain, Academic Press, 2002; 717–727, ISBN 9780122272103,

49.

Gao X, Wu D, Li X, Su B, Sun Z, Nie B, Zhang X, Wei Y. Altered glucose metabolism of the olfactory-related cortices in anosmia patients with traumatic brain injury. Eur Arch Otorhinolaryngol. 2021. https://doi.org/10.1007/s00405-021-06754-0 (Epub ahead of print).CrossRefPubMed

50.

Chiaravalloti A, Pagani M, Micarelli A, Di Pietro B, Genovesi G, Alessandrini M, Schillaci O. Cortical activity during olfactory stimulation in multiple chemical sensitivity: a (18)F-FDG PET/CT study. Eur J Nucl Med Mol Imaging. 2015;42:733–40.CrossRefPubMed

51.

Chu WJ, Mason GF, Pan JW, Hetherington HP, Liu HG, San Pedro EC, Mountz JM. Regional cerebral blood flow and magnetic resonance spectroscopic imaging findings in diaschisis from stroke. Stroke. 2002;33:1243–8.CrossRefPubMed

52.

Dietemann S, Noblet V, Imperiale A, Blondet C, Namer IJ. FDG PET findings of the brain in sudden blindness caused by bilateral central retinal artery occlusion revealing giant cell arteritis. Clin Nucl Med. 2015;40:45–6.CrossRefPubMed

53.

Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. A systematic review of the current data. Front Med (Lausanne). 2021;8:653516.CrossRefPubMedPubMedCentral

54.

Antczak J, Popp R, Hajak G, Zulley J, Marienhagen J, Geisler P. Positron emission tomography findings in obstructive sleep apnea patients with residual sleepiness treated with continuous positive airway pressure. J Physiol Pharmacol. 2007;5(Suppl. 5):25–35.

Titel: Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson’s disease (PD) do not overlap
verfasst von: Silvia Morbelli
Silvia Chiola
Maria Isabella Donegani
Dario Arnaldi
Matteo Pardini
Raffaele Mancini
Francesco Lanfranchi
Francesca D’amico
Matteo Bauckneht
Alberto Miceli
Erica Biassoni
Beatrice Orso
Emanuela Barisione
Luana Benedetti
Sambuceti Gianmario
Flavio Nobili
Publikationsdatum: 05.01.2022
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05666-9

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Usefulness of brain FDG PET/CT imaging in pediatric patients with suspected autoimmune encephalitis from a prospective study

Prediction of myocardial blood flow under stress conditions by means of a computational model

68Ga-FAPI PET/CT detected non-FDG-avid bone metastases in breast cancer

[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial

Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT

Improved myocardial blood flow estimation with residual activity correction and motion correction in 18F-flurpiridaz PET myocardial perfusion imaging